噻托溴铵对轻到中度COPD患者疗效观察

The clinic efficacy of tiotropium in patients with mild to moderate COPD

目的评价噻托溴铵对轻中度COPD患者的疗效。方法在12周时间内,轻中度COPD患者接受治疗后分别测定其1 d,15 d,85 d噻溴托按组（18 ug qd）和安慰剂组的肺功能（以给药前1 d测定值为基线）。结果两组用药前平均FEV1预计值%为73.4±12.5。试验结束时噻托溴铵组FEV1用药前及用药后2 h曲线下面积（AUC0~2 h）与安慰剂组对照,都有显著提高（P〈0.0001）。两组不良反应相似。结论噻托溴铵较安慰剂显著改善轻度COPD患者肺功能。

Objective Evaluation of tiotropium clinic efficacy in patients with mild chronic obstructive pulmonary disease（COPD）.Methods In this 12 week,randomised,double-blind,placebo-controlled study of tiotropium 18 mcg once daily versus placebo in the patients with mild to moderate COPD,their respiratory function were assessed on Days 1,15 and 85（baseline： pre-dose Day 1）.Results The mean FEV1（% predicted） of all was 73.4±12.5.The baseline in area under the curve from pre-dose to 2 hours post-dose（AUC0-2h） FEV1 in Tiotropium group significantly improved（P〈0.0001）.The rates of adverse event were similar between two groups.Conclusion Tiotropium can significantly improve the lung function in patients with mild to moderate COPD.